



## PRESS RELEASE

### Epoqe Pharma Provides Leadership Update & Strengthens US IP

- Seasoned biotech professionals join Epoqe Pharma's new board of directors;
- The board formation reflects Epoqe Pharma's ongoing corporate development;
- The directors assist the executive team in fundraising and development activities;
- Epoqe Pharma strengthens the patent position in the US with the receipt of a Notice of Allowance from the US patent office;
- Epoqe Pharma is currently raising a Series A, based on robust preclinical data established through funding support from Lundbeckfonden and Innvationsfonden.

**Copenhagen, November 21, 2023.** Epoqe Pharma, a pre-clinical-stage biopharmaceutical company focused on the development of novel treatments for serious cardiovascular diseases, with the primary indication being Acute Myocardial Infarct (AMI), announces today that a board of directors has been established, reflecting the growth and further development of Epoqe Pharma.

The board of directors of Epoqe Pharma comprises of:

**Jan Bjerrum Bach:** Seasoned attorney and biotech professional with more than 30 years of life sciences experience. Comprehensive biotech start-up experience, including in relation to capital raising and exit transactions.

**Alejandra Mørk:** Former CEO of KLIFO, Experienced CRO and pharma executive. Expert within drug development, regulatory affairs and clinical development.

**Anders Gaarsdal Holst:** Chief Executive Officer and Chief Medical Officer at Acesion Pharma. Medical doctor with clinical background in cardiology. Extensive experience in cardiovascular and metabolic disease clinical development.

Epoqe Pharma's first-in-class drug concept originates from our CEO, Anette Sams' research from Copenhagen University, Novo Nordisk and Copenhagen University Hospital. This research elucidated unique heart rescue properties of specific peptides, offering a promising avenue for treating a wide range of cardiovascular diseases.



## NOTES FOR EDITORS

### About Epoqe Pharma

Based in Copenhagen, Denmark, Epoqe Pharma is a pre-clinical stage biopharmaceutical company focused on the development of novel treatments for cardiovascular diseases. The company is currently developing a first-in-class therapy to treat Acute Myocardial Infarct, a serious, sudden heart indication.

### About Acute Myocardial Infarct

Obstruction of the coronary blood flow during myocardial infarct limits oxygen supply to the heart muscle. This promotes cardiac ischemia, cardiac dysfunction and ischemic heart conditions increasing the risk of heart failure and feeding into a cardiometabolic disease acceleration loop.

Ischemic heart disease is #1 global cause of death, disability and human suffering.

For further information, please contact:

Lasse Nørregaard, CBO  
Email: [Lasse@epoqepharma.com](mailto:Lasse@epoqepharma.com)